---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Phase of product development"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Phase of product development. Topics: Investigational status, Development phase: phase 3 portion of the pivotal phase 2/3 trial, Breakthrough Therapy Designation and designated population, Other expedited program and orphan designations, and 8 further topics. 12 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Investigational status

> “This presentation discusses potential future product candidates that are investigational only and have not yet been approved for marketing by the U.S. Food and Drug Administration.”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.1.1-2"></a>

### Development phase: phase 3 portion of the pivotal phase 2/3 trial

> “In January 2026, we announced that 1500mg QW of ficerafusp alfa was selected as the optimal dose to bring forward in the Phase 3 portion of the FORTIFI-HN01 trial.”
> “In February 2026, the transition to the Phase 3 portion of the FORTIFI-HN01 trial was completed.”
> “We enrolled the first patients in Phase 2 of the FORTIFI-HN01 trial in February 2025.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-3"></a>

### Breakthrough Therapy Designation and designated population

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.”
> “BTD was supported by results from multiple Phase 1/1b dose cohorts evaluating ficerafusp alfa in combination with pembrolizumab in patients with 1L HPV-negative R/M HNSCC.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.1.1-4"></a>

### Other expedited program and orphan designations

> “In addition, we may seek fast-track designation for our potential product candidates in the future.”
> “We may not be able to obtain orphan drug designation for any indications for our product candidates, and we may not be able to maintain such designations if granted.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-5"></a>

### FDA alignment on the accelerated approval pathway and confirmatory overall survival

> “As a result of our discussions with the FDA, we believe that ficerafusp alfa has a path to accelerated approval using an ORR-based interim endpoint with confirmatory approval based on an OS endpoint.”
> “We believe the trial can support an accelerated approval on the basis of overall response rate, or ORR, six-month durability, and qualitative OS.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.1-6"></a>

### FDA alignment on the phase 3 dose

> “Bicara has aligned with the U.S. Food and Drug Administration (FDA) on a clear path to implement, by the end of the first quarter, the optimal dose for Phase 3 of FORTIFI-HN01”

Source: [Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides)

<a id="topic-2.1.1-7"></a>

### Regulatory status: Submission planned; BLA for accelerated approval to follow an interim analysis expected in mid-2027

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”
> “Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for Biologics License Application, or BLA, submission and FDA approval of ficerafusp alfa or any future product candidates or for similar applications to and approvals by foreign regulatory authorities.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “The primary endpoints are overall response rate based on RECIST v1.1 and overall survival, with results potentially supporting regulatory filings for both accelerated approval and full approval.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

> “Expect topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC in mid-2027.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.1-8"></a>

### Launch: Anticipated in 2028

> “Interim analysis expected mid-2027 and potential U.S. launch in 2028”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.1.1-9"></a>

### Alternate dosing study timed to the potential approval

> “We expect to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-10"></a>

### Ongoing phase 1b cohorts outside the pivotal population

> “We are continuing to enroll a Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with 1L R/M HPV-negative HNSCC with a CPS<1.”
> “We are continuing to enroll an additional Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with HPV-positive R/M HNSCC and a history of heavy smoking.”
> “We are continuing to enroll Phase 1b expansion cohorts evaluating 1500mg QW of ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients”
> “with third-line metastatic colorectal cancer with microsatellite stable RAS/BRAF wild-type. We expect to present data from these cohorts in January 2027.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “we believe there is an opportunity to expand the development of ficerafusp alfa in combination with pembrolizumab to the approximately 20% of the R/M HNSCC that do not express PD-L1 and provide a chemotherapy-free alternative.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.1-11"></a>

### Cutaneous squamous cell carcinoma and squamous cancer of the anal canal

> “In 2025, we presented data from additional Phase 1b cohorts evaluating ficerafusp alfa monotherapy in patients with second-line or later cutaneous squamous cell carcinoma, as well as ficerafusp alfa in combination with pembrolizumab in patients with second-line or later squamous cancer of the anal canal.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-12"></a>

### Investigator-sponsored trials in head and neck cancer

> “In late 2025, we supported an investigator-sponsored trial to signal-seek in several areas in LA-HNSCC, including in the neoadjuvant setting.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease”

Source: [ClinicalTrials.gov NCT07529873](https://clinicaltrials.gov/study/NCT07529873)

> “Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial”

Source: [ClinicalTrials.gov NCT07465276](https://clinicaltrials.gov/study/NCT07465276)

> “Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)”

Source: [ClinicalTrials.gov NCT07552558](https://clinicaltrials.gov/study/NCT07552558)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
